top of page

Global Medical Supply Chains: Challenges and Opportunities


Shortfalls of critical supplies like protective equipment, ventilators, and pharmaceuticals have impacted health systems’ ability to respond effectively across the world. Strengthening the resilience and agility of medical supply chains is imperative to prepare for future periods of unusually high demand. 


Structural weaknesses exist in today’s global medical supply chain which can be addressed through enhanced planning, coordination, and predictive modeling. Opportunities to increase resilience involve creating redundancies, building advanced analytics, and improving visibility across the end-to-end chain. Doing so will help ensure reliable supply availability to meet urgent needs during times of strained global capacity. 


Investing now to create buffers and flexibility is key to ensuring reliable supply availability during volatile or unexpected market conditions.


Drivers of Current Medical Supply Chain Models


To understand the key vulnerabilities, it is useful to examine some of the historical trends that shaped today’s medical product supply chains. Supply chains for pharmaceuticals, medical devices, and healthcare commodities have become increasingly globalized over the past several decades. 


Manufacturing and production activities are concentrated in geographic clusters where specialized expertise, infrastructure, and ecosystems are developed. For example, the U.S. offshored over 97% of antibiotic production to China and India, given the massive investments these countries made in chemical synthesis capacities. Similar concentration occurred across other healthcare products.


A few key factors drove this increased globalization and specialization:

  • Cost Control: Outsourcing and offshoring production of healthcare products to emerging markets with lower labor and materials costs reduced expenses substantially. Given continual downward pressure on healthcare spending in key markets like the U.S., medical product companies aggressively optimized for cost competitiveness.

  • Access to Talent and Innovation: Emerging markets also developed talented biomedical, pharmaceutical, and engineering workforces, along with innovation ecosystems, attracting medical product companies. India is a standout example, now producing over 60% of the world’s vaccines.

  • Economies of Scale: Globalized networks allowed medical products firms to scale up production significantly and capture greater efficiency gains. High fixed costs also incentivized concentration into fewer, large facilities rather than many smaller sites.


Key Supply Chain Challenges Exposed by COVID-19


While the drivers above improved cost and efficiency metrics, the tradeoffs regarding supply chain resilience have become starkly clear. Key weaknesses included:


Overspecialization

Many supply chains concentrated production of critical medical supplies like masks, gowns, testing reagents or drugs in one geographic region. For example, China manufactured 50% of the world’s face masks before the pandemic. India and China combined produced 90% of all paracetamol. This lack of diversification created extreme vulnerability. When regions like Hubei, China - center of mask production - were overwhelmed by COVID-19, enormous supply shortfalls resulted.


Lack of Visibility and Data Sharing

Today’s medical supply chains involve numerous companies spanning different continents and steps from raw materials to final product. However, end-to-end visibility across the full chain is limited. Most companies focus narrowly on optimizing performance only within their segment of the chain rather than holistically. Proprietary data systems also inhibit more open and real-time data sharing between companies. 


Surge Capacity Gaps

As the pandemic took hold, global demand for critical medical supplies spiked beyond existing manufacturing capacity. However, companies had struggled to maintain unused “surge” capacities at all times, given the expense and low utilization. Despite urgent need, rapidly scaling up production was extremely difficult across long, complex supply chains. Governments urgently attempted to mobilize excess manufacturing capacity in industries like automotive or consumer electronics to re-tool for things like ventilators and testing kits. But progress was slow.


Opportunities to Improve Resilience Moving Forward

Given the supply chain stress test provided by COVID-19, strengthening resilience and flexibility is now a priority for both public and private sector stakeholders. Opportunities span policy, technology, and partnership domains:


Diversify Supply Networks

  • Governments can consider incentives to encourage localized production and build regional self-sufficiency regarding medical supplies as risks of global network disruption increase. The desired level of redundancy must be balanced with efficiency.

  • Suppliers can design products for “multi-sourcing,” using more modular designs that enable production via multiple facilities rather than a single site of origin.


Invest in Visibility and Coordination Infrastructure

  • New technologies like blockchain, artificial intelligence, and cloud-based supply chain analytics can enable enhanced end-to-end visibility and rapid information sharing across medical supply chains.

  • Private sector manufacturers and logistics firms must strengthen partnerships with public sector agencies involved in emergency response coordination. Common data standards and integrated IT systems can better align planning.


Create Surge Manufacturing Plans

  • Medical product companies can conduct stress tests to identify vulnerabilities when demand spikes and create mitigation plans, for example, by maintaining molding equipment for PPE in storage.

  • Partnerships with military organizations offer useful lessons as they maintain extensive expertise in emergency supply chain operations. Coordinated public-private planning around excess manufacturing capacity and stockpiling can also help develop scalable surge plans.


Conclusion

While the complexity and specialization of modern medical supply chains enabled major efficiencies and cost reductions, this came at the expense of built-in resilience. As health crises become more common in our interconnected world, we must balance these two crucial supply chain aspects. 


Targeted investments in IT infrastructure, coordinated partnerships between industry and government, redundancy in production, and advanced planning for disruptions can help achieve this balance. Global collaboration will be key - our collective health security depends on resilient, agile supply chains capable of flexibly responding to the great challenges ahead.


10 views0 comments

Comments


bottom of page